Proton pump inhibitors: Risks of long-term use

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 7, 2017, Pages 1295-1302

  Eusebi, Leonardo Henry ^a,b   Rabitti, Stefano ^a   Artesiani, Maria Laura ^a   Gelli, Dania ^a   Montagnani, Marco ^a   Zagari, Rocco Maurizio ^a   Bazzoli, Franco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

complications; long term risk; proton pump inhibitor

Indexed keywords

CLOPIDOGREL; MINERAL; PROTON PUMP INHIBITOR; VITAMIN; CALCIUM; TICLOPIDINE;

ADVERSE DRUG REACTION; CALCIUM ABSORPTION; CARDIOVASCULAR RISK; COLON CANCER; DEMENTIA; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG MECHANISM; DRUG USE; FRACTURE; HUMAN; INTESTINE INFECTION; KIDNEY DISEASE; LONG TERM CARE; META ANALYSIS (TOPIC); NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER; STOMACH CARCINOID; STOMACH POLYP; SYSTEMATIC REVIEW (TOPIC); ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG INTERACTION; GASTROINTESTINAL TUMOR; INTESTINE ABSORPTION; METABOLISM; RISK; TIME FACTOR;

CALCIUM; CARDIOVASCULAR DISEASES; DEMENTIA; DRUG INTERACTIONS; FRACTURES, BONE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTESTINAL ABSORPTION; KIDNEY DISEASES; PNEUMONIA; PROTON PUMP INHIBITORS; RISK; TICLOPIDINE; TIME FACTORS; VITAMINS;

EID: 85021047113     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13737     Document Type: Review

References (75)

1. Johnson DA, Oldfield EC. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin. Gastroenterol. Hepatol. 2013; 11: 458–464; quiz e37-8.
2. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am. J. Gastroenterol. 2011; 106: 1209–1218; quiz 19.
3. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos. Int. 2015.
4. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren. Fail. 2015; 37: 1237–1241.
5. Cardoso RN, Benjo AM, DiNicolantonio JJ et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015; 2: e000248.
6. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 2012; 107: 1011–1019.
7. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am. J. Gastroenterol. 2012; 107: 1001–1010.
8. Tleyjeh IM, Bin Abdulhak AA, Riaz M et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012; 7: e50836.
9. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015; 10: e0128004.
10. Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J. Gastroenterol. 2013; 19: 2560–2568.
11. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst. Rev. 2014; 12: CD010623.
12. Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J. Lab. Clin. Med. 1978; 92: 108–116.
13. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig. Dis. Sci. 2011; 56: 2349–2353.
14. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007; 56: 1291–1295.
15. Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. Neurology 1995; 45: 1435–1440.
16. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310: 2435–2442.
17. den Elzen WP, Groeneveld Y, de Ruijter W et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment. Pharmacol. Ther. 2008; 27: 491–497.
18. Schenk BE, Festen HP, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment. Pharmacol. Ther. 1996; 10: 541–545.
19. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N. Engl. J. Med. 2006; 355: 1834–1836.
20. Food and Drug Administration. FDA Drug Safety Communication: Low Magnesium Levels Can Be Associated with Long-Term Use of Proton Pump Inhibitor Drugs (PPIs). Silver Spring, MD: Available at: http://www.fda.gov/drugs/drugsafety/ucm245011.htmUS Food and Drug Administration, 2011.
21. Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern. Med. 2016; 176: 172–174.
22. Recker RR. Calcium absorption and achlorhydria. N. Engl. J. Med. 1985; 313: 70–73.
23. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am. J. Med. 2005; 118: 778–781.
24. Serfaty-Lacrosniere C, Wood RJ, Voytko D et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J. Am. Coll. Nutr. 1995; 14: 364–368.
25. Nordin BE. Calcium and osteoporosis. Nutrition 1997; 13: 664–686.
26. Sheraly AR, Lickorish D, Sarraf F, Davies JE. Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr. Drug Deliv. 2009; 6: 192–198.
27. Food and Drug Administration 2010. FDA drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Silver Spring, MD: US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/postmarketdrugsafetyInformationforpatientsandproviders/ucm213206.htm-TableofEpidemiologicalStudiesevaluatingfractureriskwithprotonpumpinhibitors.
28. Majumdar A, Cruz D, Asamoah N et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol. Biol. Cell 2007; 18: 1490–1496.
29. Haenisch B, von Holt K, Wiese B et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur. Arch. Psychiatry Clin. Neurosci. 2015; 265: 419–428.
30. Gomm W, von Holt K, Thome F et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016; 73: 410–416.
31. Food and Drug Adminstration 2009. FDA Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm.
32. Shah NH, LePendu P, Bauer-Mehren A et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015; 10: e0124653.
33. Melloni C, Washam JB, Jones WS et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ. Cardiovasc. Qual. Outcomes 2015; 8: 47–55.
34. Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad. Med. 2014; 126: 239–245.
35. Otake K, Sakurai Y, Nishida H et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv. Ther. 2016; 33: 1140–1157.
36. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J. Nephrol. 2016.
37. Antoniou T, Macdonald EM, Hollands S et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015; 3: E166–E171.
38. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case–control study. BMC Nephrol. 2013; 14: 150.
39. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case–control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014; 86: 837–844.
40. Lazarus B, Chen Y, Wilson FP et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med. 2016; 176: 238–246.
41. Arora P, Golzy M, Gupta A, Ranjan R, Carter R, Lohr J. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease [Abstract]. J. Am. Soc. Nephrol. 2015; 26: 219A.
42. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J. Am. Soc. Nephrol. 2016.
43. Reimer C. Safety of long-term PPI therapy. Best Pract. Res. Clin. Gastroenterol. 2013; 27: 443–454.
44. Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr. Opin. Endocrinol. Diabetes Obes. 2014; 21: 3–8.
45. Clooney AG, Bernstein CN, Leslie WD et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment. Pharmacol. Ther. 2016; 43: 974–984.
46. Imhann F, Bonder MJ, Vich Vila A et al. Proton pump inhibitors affect the gut microbiome. Gut 2016; 65: 740–748.
47. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharmacol. Ther. 2011; 34: 1269–1281.
48. Brophy S, Jones KH, Rahman MA et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am. J. Gastroenterol. 2013; 108: 1094–1100.
49. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin. Gastroenterol. Hepatol. 2013; 11: 483–490.
50. Bajaj JS, Cox IJ, Betrapally NS et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am. J. Physiol. Gastrointest. Liver Physiol. 2014; 307: G951–G957.
51. Kwon JH, Koh SJ, Kim W et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J. Gastroenterol. Hepatol. 2014; 29: 775–781.
52. Bajaj JS, Heuman DM, Hylemon PB et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 2014; 60: 940–947.
53. Deshpande A, Pasupuleti V, Thota P et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J. Gastroenterol. Hepatol. 2013; 28: 235–242.
54. Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment. Pharmacol. Ther. 2015; 41: 459–466.
55. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955–1960.
56. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case–control study. Pharmacoepidemiol. Drug Saf. 2010; 19: 792–802.
57. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann. Intern. Med. 2008; 149: 391–398.
58. Schneider JL, Kolitsopoulos F, Corley DA. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment. Pharmacol. Ther. 2016; 43: 73–82.
59. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, De Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment. Pharmacol. Ther. 2006; 24: 1341–1348.
60. Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2016; 14: 1706–1719.e5.
61. Zelter A, Fernandez JL, Bilder C et al. Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig. Dis. Sci. 2011; 56: 1743–1748.
62. Genta RM, Schuler CM, Robiou CI, Lash RH. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin. Gastroenterol. Hepatol. 2009; 7: 849–854.
63. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55: 1217–1221.
64. Poulsen AH, Christensen S, McLaughlin JK et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br. J. Cancer 2009; 100: 1503–1507.
65. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter 2014; 19: 1–5.
66. Hagiwara T, Mukaisho K, Nakayama T, Hattori T, Sugihara H. Proton pump inhibitors and helicobacter pylori-associated pathogenesis. Asian Pac. J. Cancer Prev. 2015; 16: 1315–1319.
67. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence consensus report. Gut 2012; 61: 646–664.
68. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment. Pharmacol. Ther. 2012; 36: 37–47.
69. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment. Pharmacol. Ther. 2015; 42: 649–663.
70. Ezekwudo D, Tobi M. Letter: long-term use of proton pump inhibitors and risk of neuroendocrine tumours. Aliment. Pharmacol. Ther. 2016; 43: 749.
71. Waldum HL, Hauso O, Brenna E, Qvigstad G, Fossmark R. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man? Scand. J. Gastroenterol. 2016; 51: 767–773.
72. Watson SA, Durrant LG, Crosbie JD, Morris DL. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int. J. Cancer 1989; 43: 692–696.
73. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748–754.
74. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case–control study. Gastroenterology 2007; 133: 755–760.
75. van Soest EM, van Rossum LG, Dieleman JP et al. Proton pump inhibitors and the risk of colorectal cancer. Am. J. Gastroenterol. 2008; 103: 966–973.